期刊文献+

紫杉醇联合顺铂治疗晚期三阴性乳腺癌的临床观察 被引量:5

Observe of paclitaxel combined with cisplatin on triple negative metastatic breast cancer
在线阅读 下载PDF
导出
摘要 目的观察紫杉醇联合顺铂治疗晚期三阴性乳腺癌的临床疗效及不良反应。方法采用紫杉醇联合顺铂治疗晚期三阴性乳腺癌30例。紫杉醇135 mg/m2静脉滴注第1天,顺铂70 mg/m2静脉滴注第2天,加水化、止吐治疗,21 d为1个周期。结果 30例均可评价疗效,总有效率47%(14/30),中位疾病进展时间7.8个月。1 a生存率60%,3 a生存率21%。其中,初治有效率58%,复治有效率27%,二者比较有显著性差异(P〈0.05)。主要不良反应为骨髓抑制、胃肠道反应、肌肉关节疼痛、周围神经毒性、肝功能异常,多为Ⅰ~Ⅱ度;Ⅲ~Ⅳ度不良反应主要为白细胞减少和胃肠道反应,发生率分别为30%和13%,未见因毒副反应而终止治疗者,无治疗相关性死亡。结论紫杉醇联合顺铂治疗晚期三阴性乳腺癌具有较好的疗效,不良反应可耐受。 Objective It is to observe the efficacy and safety of Paclitaxel-Cisplatin Protocol in triple negative metastatic breast cancer.Methods 30 patients with triple negative metastatic breast cancer were treated with combination of Paclitaxel and Cisplatin.Paclitaxel was administered at 135 mg/m2 intravenous drip d1,and Cisplatin was administered at 70 mg/m2 intravenous drip d2.The above protocolwas repeated every 21 days.Results The total effective rate was 47%,with a median time to progression of 7.8 months.The median 1-year survival rate was 60%.The median 3-year survival rate was 21%.The total effective rate was 58% in patients with initial treatment and 27% in patients with retreatment,there was significant difference between them(P0.05).The main side effects were myelosuppression,arthralgia,muscle pain,peripheral neuropathy,gastrointestinal toxicity and abnormal hepatic function.Most of the above side effects were grade Ⅰ~Ⅱ.The main grade Ⅲ~Ⅳ side effects were leukopenia and gastrointestinal toxicity with an incidence of 30% and 13% respectively.There was no death during treatment.Conclusion The combined of paclitaxel and cisplatin has high efficacy in patiens with triple negative metastatic breast cancer.The side effects are tolerable.
出处 《现代中西医结合杂志》 CAS 2010年第33期4250-4252,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 紫杉醇 顺铂 晚期三阴性乳腺癌 化疗 Paclitaxel Cisplatin triple negative metastatic breast cancer chemotherapy
  • 相关文献

参考文献11

  • 1王晓稼,Kevin R.Fox.受体三阴性乳腺癌的分子特征与治疗研究进展[J].癌症进展,2008,6(2):129-134. 被引量:4
  • 2蔡铭泉,陈强,施纯枚.受体三阴性乳腺癌的研究进展[J].临床肿瘤学杂志,2009,14(3):283-287. 被引量:17
  • 3Tan DS,Marchió C,Jones RL,et al.Triple negative breast cancer:molecular profiling and prognostic impact in adjuvant an thracycline-treated patients[J].Breast Cancer Res Treat,2007,10(6):512-515.
  • 4Geisler S,Lonning PE,Aas T,et al.Influence of TP53 gene alterations and c-erb B-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer[J].Cancer Research,2001,61(6):2505-2512.
  • 5James CR,Quinn JE,Mullan PB,et al.BRCA1,a potential predictive biomarker in the treatment of breast cancer[J].Oncologist,2004,12(2):142-150.
  • 6周际昌.实用肿瘤内科学[M].2版.北京:人民卫生出版社,2005:92-94.
  • 7Naumova E,Ubezio P,Garofalo A,et al.The vascular targeting property of paclitaxel is enhanced by SU6668,a receptor tyrosine kinase inhibitor,causing apoptosis of endothelial cells and inhibition of angiogenesis[J].Clin Cancer Res,2006,12(6):1839-1849.
  • 8Hortobagyi GN,Hoimes FA.Single-agent paclitaxel for the treatme-nt of breast cancer:An overview[J].Semin Oncol,1996,23(Supp11)∶4.
  • 9Decatris MP,Sundar S,O'Byme KJ.Platinum-based chemotherapy in metastatic breast cancer:current status[J].Cancer Treat Rev,2004,30(1):53-81.
  • 10王佳玉,徐兵河,张频,李青.紫杉醇联合顺铂治疗57例晚期乳腺癌的临床疗效分析[J].中华肿瘤防治杂志,2007,14(9):695-697. 被引量:11

二级参考文献77

  • 1徐兵河,赵龙妹,王佳玉,袁芃.泰索帝联合顺铂治疗31例蒽环类耐药性晚期乳腺癌疗效分析[J].中华肿瘤杂志,2006,28(6):471-473. 被引量:46
  • 2Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[ J]. Nature ,2000,406 : 747 - 752.
  • 3Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochenical and clinical characterization of the basal-like subtype of invasive breast carcinoma [ J ]. Clin Cancer Res, 2004,10 ( 16 ) :5367 - 5374.
  • 4Bertucci F. How basal are triple-negative breast cancers? [ J]. Int J Cancer,2008,123 ( 1 ) : 936 - 240.
  • 5Sasa M, Bando Y,Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy tbr triple-negative breast cancer [ J ]. J Surg Oncol, 2008,97 ( 1 ) : 30-34.
  • 6Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options [ J ]. Lancet Oncol,2007,8 : 235 - 244.
  • 7Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCAI mutations and a basal epithelial phenotype in breast cancer[J]. J Natl Cancer Inst,2003,95 : 1482 - 1485.
  • 8Korsehing E, Packeisen J, Agelopoulos K,et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenelic pathways of breast carcinogenesis[ J ]. Lab Invest,2002,82 : 1525 - 1533.
  • 9Foulkes WD, Brunet JS, Stefansson IM,et al. The prognostic implication of the basal-like (cyclin E^high/p27^low/p53^+/ glomeruloid-microvascular-proliferation^+ ) phenotype of BRCA1-related breast cancer[ J]. Cancer Res,2004, 64 : 830 - 835.
  • 10Bergamaschi A, Kim YH,Wang P,et al. Distinct patterns of DNA copy number alteration are associated with different clinieopathological features and gene-expression subtypes of breast cancer [ J]. Genes Chromosomes Cancer, 2006,45 : 1033 - 1040.

共引文献118

同被引文献42

  • 1罗智辉,孔令言.紫杉醇联合顺铂的新辅助化疗治疗乳腺癌的临床观察[J].热带医学杂志,2005,5(5):693-694. 被引量:2
  • 2Kejin Wu, Ziyi Weng, Qinghua Tao, et al. Stage-specific expression of breast cancer-specific gene ~/-synuclein[J]. Cancer Epidemiology Biomarkers Prevention, 2003,12 (9) :920.
  • 3Harry D. Bear, Stewart Anderson, Roy E. Smith, et al. Sequential preoperative or postoperative docetaxel added to preoperative Doxorubiein Plus Cyelophos phamide for Operable breast cancer: National surgical adjuvant breast and bowel project protocol B-27 [J]. American Society of Clinical Ontology, 2006,24 (13) : 2019-2027.
  • 4B Sirohi, M Arnedos,S Popat,et al. Platinum-based chemotherapy in triple-negative breast cancer[J]. AnnOneol, 2008,19 ( 11 ) : 1847-1852.
  • 5王殊,杨后圃,张嘉庆,等.三阴性乳腺癌的新辅助化疗疗效及预后分析[C].第五届中国肿瘤学术大会教育集.557-560.
  • 6Caldarella A, Crocetti E, Bianchi S, et al. Female breast cancer status according to ER, PR and HER2 expression: a population based analysis[J]. Pathol Oncol Res, 2011, 17:753-758.
  • 7Chen JQ, Russo J. ERa-negative and triple negative breast canc- er: molecular features and potential therapeutic approaches [ J ]. Biochim Biophys Acta, 2009, 1796 : 162-175.
  • 8Joh JE, Han G, Kiluk JV, et al. Indications for axillary ultra- sound use in breast cancer patients [ J ]. Clin Breast Cancer, 2012, 12:433-437.
  • 9陈馨,王雪晨,姚永忠,仇毓东,袁毅路,张双玲.新辅助化疗乳腺癌对雌激素、孕激素受体表达的影响及意义[J].实用医学杂志,2008,24(23):4066-4068. 被引量:15
  • 10吴海鹰,管忠震,林桐榆,蔡树模,许立功,黄荣丽,黄惠芳,李龙芸,鲍云华,江泽飞.国产紫杉醇治疗恶性肿瘤的Ⅱ期临床研究[J].中华肿瘤杂志,1998,20(2):148-152. 被引量:95

引证文献5

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部